XML 27 R15.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2021

6. Inventories

The Group’s inventory balance of $12,494 and $13,144 as of September 30, 2021 and December 31, 2020, respectively, mainly consisted of finished goods purchased from Tesaro Inc., now GlaxoSmithKline (GSK), for distribution in Hong Kong, and from NovoCure Limited (“NovoCure”) and Deciphera Pharmaceuticals, LLC (“Deciphera”) for distribution in Hong Kong and China, as well as finished goods and certain raw materials for ZEJULA commercialization in China.


	As of

	September 30, 2021		December 31, 2020

	$		$
Finished goods		5,298		3,041
Raw materials		7,196		10,103

Inventories		12,494		13,144

The Group writes down inventory for any excess or obsolete inventories or when the Group believes that the net realizable value of inventories is less than the carrying value. During the three and nine months ended September 30, 2021, the Group recorded write-downs of

$112 and $402,

in cost of revenues, respectively. During the three and nine months ended September 30, 2020, the Group recorded reverses and write-downs of

$7 and nil,

in cost of revenues, respectively.